Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sucrose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.71 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.71 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sucrose SCHEMBL28599766 | 1.00 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL28363308 | 1.00 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL18742105 | 0.99 | CDK1 (0.70) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL10405566 | 0.99 | CDK1 (0.73) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL367818 | 0.99 | CDK1 (0.73) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL5972243 | 0.97 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL9704445 | 0.97 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL15656196 | 0.97 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL9747719 | 0.97 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL6376479 | 0.97 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5023072-A | Paramagnetic/superparamagnetic/ferromagnetic sucrose sulfate compositions for magnetic resonance imaging of the gastrointestinal tract | UNIVERSITY OF NEW MEXICO (US) | 1991-06-11 | — | — | US | claimed |
| US-20100055040-A1 | Optical Imaging Contrast Agents | MALLINCKRODT INC. | 2010-03-04 | — | — | US | disclosed |
| CN-101203248-A | Optical imaging contrast agents | MALLINCKRODT INC (US) | 2008-06-18 | — | — | CN | disclosed |
| EP-1901781-A2 | OPTICAL IMAGING CONTRAST AGENTS | MALLINCKRODT, INC. (US) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007002332-A2 | OPTICAL IMAGING CONTRAST AGENTS | MALLINCKRODT INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-1994000476-A1 | USE OF WATER-SOLUBLE SUCROSES FOR THE TREATMENT AND/OR PREVENTION OF LESION OR INFLAMMATION IN THE DIGESTIVE TRACT | BUKH MEDITEC A/S (DK) | 1994-01-06 | — | — | WO | disclosed |
| US-5023072-A | Paramagnetic/superparamagnetic/ferromagnetic sucrose sulfate compositions for magnetic resonance imaging of the gastrointestinal tract | UNIVERSITY OF NEW MEXICO (US) | 1991-06-11 | — | — | US | disclosed |
| US-4851209-A | Diagnostic procedures using radio labeled sucralfate and derivatives or precursors thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1989-07-25 | — | — | US | disclosed |
| US-4581221-A | TECHNETIUM LABELLED CARRIER REACTED WITH AN ULCER SPECIFIC OLIGOSACCHARIDE SULFATE | MEDI NUCLEAR CORPORATION, INC. (US) | 1986-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100055040-A1 | Optical Imaging Contrast Agents | SI, FABP2, ALPI | CDK1 3653/4885CCNB1 4043/4885CA2 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.